GSK Commences Tender Offer for Nuvalent Acquisition at $124/Share
GSK sits 46% above its 52-week low of $35.45 on light trading volume (0.2× avg).
Summary
GSK has formally launched its tender offer to acquire Nuvalent, Inc. for $124.00 per share, moving forward with the previously announced $10.6 billion acquisition to bolster its oncology portfolio.
Key Events · M&A and Partnerships · GSK
-
Tender Offer Commenced
GSK's subsidiary, Harmony Row Acquisition Co., has formally commenced a tender offer to acquire all outstanding shares of Nuvalent, Inc.
-
Acquisition Price Set
The offer price is $124.00 per share in cash for both Class A and Class B Common Stock of Nuvalent.
-
Strategic Acquisition Progresses
This tender offer is a key step in the previously announced $10.6 billion acquisition of Nuvalent, which is expected to significantly enhance GSK's oncology pipeline with late-stage lung cancer assets.
-
Offer Expiration Date
The tender offer and withdrawal rights will expire at one minute following 11:59 p.m., Eastern Time, on July 14, 2026.
Analysis · GSK · Life Sciences
This filing details the formal commencement of GSK's tender offer to acquire Nuvalent, Inc. for $124.00 per share. This is a crucial procedural step in the previously announced $10.6 billion acquisition, which aims to significantly enhance GSK's late-stage oncology pipeline, particularly in lung cancer. The tender offer is expected to expire on July 14, 2026, moving the major strategic acquisition closer to completion.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $51.68 on NYSE in the Life Sciences sector, with a market capitalization of approximately $103.5B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.